<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Reduction in cardiac (123)I-metaiodobenzylguanidine (MIBG) uptake is a characteristic feature of <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>) and <z:hpo ids='HP_0000726'>dementia</z:hpo> with <z:hpo ids='HP_0100315'>Lewy bodies</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>), and is useful in distinguishing them from other <z:e sem="disease" ids="C0524851" disease_type="Disease or Syndrome" abbrv="">neurodegenerative disorders</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to investigate the role of this method of scintigraphy in the differential diagnosis of <z:hpo ids='HP_0000726'>dementia</z:hpo> in our Memory Clinic </plain></SENT>
<SENT sid="2" pm="."><plain>We performed MIBG scintigraphy in patients with <z:hpo ids='HP_0000726'>dementia</z:hpo> referred to the Memory Clinic and compared the heart-to-mediastinum (H/M) ratio of MIBG uptake </plain></SENT>
<SENT sid="3" pm="."><plain>Thirty out of 32 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e> and <z:hpo ids='HP_0000001'>all</z:hpo> 9 PD with <z:hpo ids='HP_0000726'>dementia</z:hpo> patients had reduced H/M ratios, whereas 37 out of 40 patients with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> had <z:mpath ids='MPATH_458'>normal</z:mpath> H/M ratios </plain></SENT>
<SENT sid="4" pm="."><plain>Most patients with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>, <z:hpo ids='HP_0002145'>frontotemporal dementia</z:hpo>, and other <z:hpo ids='HP_0000726'>dementias</z:hpo> had <z:mpath ids='MPATH_458'>normal</z:mpath> H/M ratios </plain></SENT>
<SENT sid="5" pm="."><plain>The overall sensitivity to positively identify patients with <z:e sem="disease" ids="C0752347" disease_type="Disease or Syndrome" abbrv="DLB">Lewy body disease</z:e> (including <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> with <z:hpo ids='HP_0000726'>dementia</z:hpo>) was 95%, and the specificity to distinguish them from patients with other types of <z:hpo ids='HP_0000726'>dementias</z:hpo> was 87% </plain></SENT>
<SENT sid="6" pm="."><plain>MIBG scintigraphy showed a high sensitivity for the detection of <z:e sem="disease" ids="C0752347" disease_type="Disease or Syndrome" abbrv="DLB">Lewy body disease</z:e>, and also a high specificity for discrimination from other types of <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The scintigraphy may provide a valuable and adjunctive method in the diagnosis of <z:e sem="disease" ids="C0752347" disease_type="Disease or Syndrome" abbrv="DLB">Lewy body disease</z:e> and a differential diagnostic tool for patients with <z:hpo ids='HP_0000726'>dementias</z:hpo> </plain></SENT>
</text></document>